DEF: Revolution Medicines 2026 Annual Meeting Proxy Statement

Revolution Medicines has issued its 2026 proxy statement detailing director elections, auditor ratification, and executive compensation advisory votes.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for June 18, 2026, at 7:30 a.m. Pacific Time, to be held virtually.
• Stockholders will vote on the election of two Class III directors, Alexis Borisy and Mark A. Goldsmith, M.D., Ph.D.
• The meeting includes a proposal to ratify PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026.
• A non-binding advisory vote (Say-on-Pay) on the compensation of named executive officers is included.
• As of the April 23, 2026 record date, there were 212,592,561 shares of common stock outstanding.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine governance filing. While the company reports strong progress on clinical goals, the significant net loss and reliance on equity compensation are standard for a late-stage clinical biotechnology firm.

Positives

• Strong stockholder support for executive compensation, with approximately 98% of votes cast in favor of the 2025 Say-on-Pay proposal.
• Successful execution of pivotal development plans for daraxonrasib and progression of registrational opportunities for mutant-selective RAS(ON) inhibitors.
• Company achieved 146% of target for its 2025 corporate performance goals.
• Strengthened financial position through a strategic financing transaction in June 2025.

Negatives

• The company continues to report net losses, with a net loss of $1.131 billion for the fiscal year 2025.
• Significant reliance on equity-based compensation, which dilutes existing shareholders.

Risks

• Clinical development risks associated with late-stage oncology programs.
• Regulatory risks related to the approval of mutant-selective RAS(ON) inhibitors.
• Market risks and potential volatility in share price.
• Operational risks associated with scaling for global commercialization.

Future Outlook

The company intends to continue advancing its late-stage clinical oncology pipeline, specifically focusing on daraxonrasib and other mutant-selective RAS(ON) inhibitors, while preparing for potential global commercialization.

Management Comments

• The Board recommends voting FOR the election of director nominees, FOR the ratification of the independent auditor, and FOR the advisory Say-on-Pay proposal.
• Management emphasizes the importance of aligning executive compensation with long-term stockholder value and the company's strategic mission.

Industry Context

StockSavvy.ai notes that Revolution Medicines is operating in a highly competitive precision oncology space, where success is heavily dependent on clinical trial outcomes and regulatory milestones. The company's focus on RAS-addicted cancers aligns with broader industry trends prioritizing targeted therapies over traditional chemotherapy.

Comparison to Industry Standards

• The company's compensation peer group includes established biotechnology and pharmaceutical companies such as Ionis Pharmaceuticals, CRISPR Therapeutics, and Blueprint Medicines.
• The use of a mix of stock options and RSUs is consistent with standard practices in the biotechnology sector to align executive interests with long-term stock performance.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• None disclosed beyond standard indemnification agreements for directors and officers.

Stakeholder Impact

• Shareholders are requested to vote on key governance and compensation matters.
• Employees participate in equity incentive plans that align their interests with company performance.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 18, 2026.
• Tabulate and announce voting results via Form 8-K within four business days of the meeting.

Key Dates

Keywords

Revolution Medicines, RVMD, Proxy Statement, Oncology, RAS inhibitors, Executive Compensation, Corporate Governance